Integrated BioPharma, Inc. (INBP)
OTCMKTS: INBP · Delayed Price · USD
0.220
+0.003 (1.38%)
May 14, 2024, 1:46 PM EDT - Market closed

Company Description

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg.

It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.

The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products.

This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials.

The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Integrated BioPharma, Inc.
Country NJ
Founded 1979
IPO Date Oct 29, 1996
Industry Packaged Foods
Sector Consumer Staples
Employees 141
CEO Ms. Riva Kay Sheppard

Contact Details

Address:
225 Long Avenue, Building 15
Hillside, New Jersey 07205
United States
Phone 9739260816
Website ibiopharma.com

Stock Details

Ticker Symbol INBP
Exchange OTCMKTS
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001016504
CUSIP Number 45811V105
ISIN Number US45811V1052
Employer ID 22-2407475
SIC Code 2834

Key Executives

Name Position
Riva Kay Sheppard Co-Chief Executive Officer and Director
Christina Kay Co-Chief Executive Officer and Director
Dina L. Masi Senior Vice President, Chief Financial Officer and Secretary
Jamie E. Levey Head of Investor Relations

Latest SEC Filings

Date Type Title
May 10, 2024 8-K Current Report
May 10, 2024 10-Q Quarterly Report
Feb 12, 2024 8-K Current Report
Feb 12, 2024 10-Q Quarterly Report
Nov 27, 2023 8-K Current Report
Nov 16, 2023 SC 13D General statement of acquisition of beneficial ownership
Nov 14, 2023 SC 13D General statement of acquisition of beneficial ownership
Nov 9, 2023 8-K Current Report
Nov 9, 2023 10-Q Quarterly Report
Oct 27, 2023 DEF 14A Other definitive proxy statements